Your shopping cart is currently empty

(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-isomer of Thalidomide with immunomodulatory, anti-inflammatory, anticancer, anti-angiogenic, and pro-apoptotic activities, used in studying leprosy erythema nodosum and myeloma.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $56 | In Stock | In Stock | |
| 10 mg | $89 | In Stock | In Stock | |
| 25 mg | $197 | In Stock | In Stock | |
| 50 mg | $313 | In Stock | In Stock | |
| 100 mg | $562 | In Stock | In Stock | |
| 500 mg | $1,190 | - | In Stock |
| Description | (S)-Thalidomide ((S)-(-)-Thalidomide) is the S-isomer of Thalidomide with immunomodulatory, anti-inflammatory, anticancer, anti-angiogenic, and pro-apoptotic activities, used in studying leprosy erythema nodosum and myeloma. |
| In vitro | In U266 cells cultured with (S)-Thalidomide, a decrease in cell viability (IC50: 362 μM) was observed, reflecting a significant increase in apoptosis (for example, on the 3rd day at 200 μM: 40.3+/-3.1% vs. 3.2+/-0.4% on the 0th day; P<0.001). Furthermore, the expression profile of genes involved in angiogenesis and apoptosis changed, with the most significant alterations observed in the expression of apoptosis-related genes[1]. |
| In vivo | Direct exposure of embryos to (S)-Thalidomide does indeed result in limb reduction defects in chick embryos. (S)-Thalidomide affects chick limb transplantation into host embryos in a dose-dependent manner. Moreover, S-thalidomide and S-EM12 are more teratogenic than R-thalidomide and R-EM12[2]. |
| Synonyms | (S)-(-)-Thalidomide |
| Molecular Weight | 258.23 |
| Formula | C13H10N2O4 |
| Cas No. | 841-67-8 |
| Smiles | O=C1N(C(=O)C=2C1=CC=CC2)[C@@H]3C(=O)NC(=O)CC3 |
| Relative Density. | 1.2944 g/cm3 (Estimated) |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (232.35 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.